CN Mobile Logo

Search form


Ovarian Cancer

Ovarian Cancer

The FDA granted accelerated approval to rucaparib (Rubraca), a PARP inhibitor, for the treatment of women with deleterious BRCA mutation-associated ovarian cancer.

A retrospective review showed that primary cytoreductive surgery was associated with longer survival than neoadjuvant chemotherapy in women with advanced-stage epithelial ovarian cancer.

Expression of mesothelium vascular cell adhesion molecule-1 (VCAM-1) is associated with poorer overall and progression-free survival in patients with epithelial ovarian cancer, according to a retrospective analysis.

The use of surveillance did not affect survival among women with stage I malignant ovarian germ cell tumors, according to a new retrospective analysis.

Adding the WEE1 inhibitor AZD1775 to carboplatin offered enhanced response rates in women with TP53-mutated ovarian cancer that was refractory or resistant to first-line platinum-based therapy in a phase II study.

Adding seribantumab to paclitaxel failed to improved progression-free survival in unselected patients with platinum-resistant or -refractory ovarian cancer. Expression of heregulin and HER2, however, could identify a subset of patients that derive benefit from the therapy.

The oral PARP inhibitor rucaparib showed strong activity and an acceptable safety profile in women with high-grade, BRCA-mutated ovarian carcinoma who had previously received at least two lines of chemotherapy.


Subscribe to Ovarian Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.